Stereotactic ablative radiation therapy for primary lung tumors

John H. Heinzerling, Brian Kavanagh, Robert D. Timmerman

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalCancer Journal
Issue number1
StatePublished - Jan 2011


  • Stereotactic ablative radiotherapy (SABR)
  • innovative therapy
  • non-small cell lung cancer (NSCLC)
  • stage I lung cancer
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Stereotactic ablative radiation therapy for primary lung tumors'. Together they form a unique fingerprint.

Cite this